Results of the Brazilian Osteosarcoma Treatment Group studies III and IV: Prognostic factors and impact on survival

Results of the Brazilian Osteosarcoma Treatment Group studies III and IV: Prognostic factors and impact on survival

Autor Petrilli, A. S. Google Scholar
Camargo, B. de Google Scholar
Odone, V Google Scholar
Bruniera, P. Google Scholar
Brunetto, A. L. Google Scholar
Jesus-Garcia, R. Google Scholar
Camargo, O. P. Google Scholar
Pena, W. Google Scholar
Pericles, P. Google Scholar
Davi, A. Google Scholar
Prospero, J. D. Google Scholar
Alves, MTS Google Scholar
Oliveira, C. R. Google Scholar
Macedo, CRD Google Scholar
Mendes, W. L. Google Scholar
Almeida, MTA Google Scholar
Borsato, M. L. Google Scholar
Santos, T. M. dos Google Scholar
Ortega, J. Google Scholar
Consentino, E. Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
Santa Casa Misericordia
Hosp Clin Porto Alegre
Childrens Hosp Los Angeles
Resumo Purpose To evaluate the impact of chemotherapy and surgery on the outcome of osteosarcoma (OS) of the extremities and to identify prognostic factors in Brazilian patients.Patients and Methods A total of 225 patients with metastatic and nonmetastatic OS of the extremities were enrolled and assessed in two consecutive studies designed and implemented by the Brazilian Osteosarcoma Treatment Group.Results the 5-year survival and event-free survival rates for the 209 assessable patients were 50.1% and 39%, respectively; for the 178 patients with nonmetastatic disease at diagnosis, the rates were 60.5% and 45.5%, respectively. the multivariate analysis showed that the following variables were associated with a shorter survival: metastases at diagnosis (P < .001), necrosis grades 1 and 2 (P = .046), and tumor size (P = .0071).Conclusion the overall 5- and 10-year survival rates were lower than the rates reported in North American and European trials. A pattern of advanced disease at diagnosis was often present, with a high proportion of patients having metastases (20.8%) and large tumor size (42.9%). However, these features were not necessarily associated with longer duration of prediagnostic symptoms. These findings were considered in the strategic planning of the current Brazilian cooperative study, with the aim of improving survival and quality of life of a large number of patients with OS.
Idioma Inglês
Data de publicação 2006-03-01
Publicado em Journal of Clinical Oncology. Alexandria: Amer Soc Clinical Oncology, v. 24, n. 7, p. 1161-1168, 2006.
ISSN 0732-183X (Sherpa/Romeo, fator de impacto)
Publicador Amer Soc Clinical Oncology
Extensão 1161-1168
Fonte http://dx.doi.org/10.1200/JCO.2005.03.5352
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000235780800023
Endereço permanente http://repositorio.unifesp.br/handle/11600/28787

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta